RTRyan Thé

Ryan Thé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan Thé has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and Efficacy of the Ahmed ClearPath versus Ahmed ClearPath Small Tube at Six Months: A Retrospective Comparative Cohort Study

    by Kelvin Sy Shi, Emily Aashna Dorairaj, Shibal Bhartiya, Kody Oyama, Weiwei Wang, Ryan Y Thé, Kevin Bryce Moreno, Melanie Wang, Caleb Towne, Ibrahim M Qozat, et al.

    Purpose: To compare the safety and efficacy of the Ahmed ClearPath® (ACP) and Ahmed ClearPath® Small Tube (ACP-ST) in the management of glaucoma. Methods: This retrospective comparative study included 15 ACP eyes and 15 ACP-ST eyes. Outcomes compared through 6 months included intraoperative pressure (IOP), medication burden, surgical success, BCVA, and complications. Complete surgical success was definied as a ≥ 20% reduction in IOP from baseline with postoperative IOP > 5 mmHg and no additional glaucoma surgery or medication. Results: Baseline IOP and medication were similar between cohorts. At 6 months, mean IOP decreased from 28.13 ± 7.68 to 10.73 ± 3.63 mmHg in the ACP cohort (p < 0.0001) and from 27.15 ± 6.72 to 12.00 ± 5.32 mmHg in the ACP-ST cohort (p = 0.0001), with no significant difference between groups (p = 0.4535). Mean medication use decreased from 2.93 ± 0.80 to 0.73 ± 1.03 in the ACP cohort (p = 0.0005) and from 3.47 ± 1.46 to 1.00 ± 1.00 in the ACP-ST cohort (p < 0.0001), with no significant difference between groups (p = 0.4785). No intraoperative complications, postoperative hypotony, or IOP spikes occurred in either cohort. Conclusions: Preliminary findings suggest that the ACP-ST may achieve IOP and medication reductions comparable to the ACP through 6 months. No postoperative hypotony was observed in the ACP-ST cohort despite the absence of tube ligation. However, given the sample size and differences in surgical technique, larger prospective controlled studies are needed to determine whether the smaller lumen independently contributes to flow control.

  • Open Access

    Novel Non-Valved Glaucoma Drainage Device with Reduced Inner Lumen Diameter: 6-Month Safety and Efficacy Outcomes

    by Kelvin Sy Shi, Pranav Vasu, Kody Oyama, Ryan Y Thé, Melanie Wang, Raphael G Banoub, Bryan Ch Ang, Syril K Dorairaj

    Purpose: To evaluate the safety and clinical efficacy of the Ahmed ClearPath® Small Tube (ACP-ST), a novel non-valved glaucoma drainage device with a reduced inner lumen diameter, in the management of glaucoma. Methods: This retrospective chart review included 17 eyes that underwent ACP-ST implantation between February 25, 2025, and November 24, 2025. Surgical success was defined as a ≥ 20% reduction in IOP from baseline with a postoperative IOP > 5 mmHg and no need for additional surgical intervention. Changes in IOP, glaucoma medication burden, and best-corrected visual acuity (BCVA) were evaluated through 6 months. Intraoperative and postoperative complications were recorded. Results: Fourteen eyes had available 6-month follow-up data. Mean IOP decreased from 27.19 ± 6.29 mmHg at baseline to 12.21 ± 5.45 mmHg at 6 months, representing a 55.1% reduction (P < 0.0001). Mean glaucoma medication use decreased from 3.35 ± 1.14 to 1.07 ± 0.99 medications, corresponding to a 68.1% reduction (P < 0.0001). Surgical success was achieved in all 14 eyes (100%) with available 6-month follow-up. No intraoperative complications occurred, and no cases of postoperative hypotony or IOP spikes were observed. Conclusion: These preliminary findings suggest that ACP-ST may achieve clinically meaningful reductions in IOP and glaucoma medication burden while maintaining a favorable short-term safety profile, as no cases of postoperative hypotony or IOP spikes were observed. However, given the retrospective design, small sample size, and limited duration of follow-up, further longitudinal studies with larger cohorts will be necessary to better evaluate the durability and long-term safety of ACP-ST.


  • Open Access

    Early Safety and Efficacy Outcomes of a Novel 360° Canaloplasty Device in Open-Angle Glaucoma: A Retrospective Cohort Study

    by Kelvin Shi, Emily Dorairaj, Melanie Wang, Ryan Thé, Pranav Vasu, Yazan Abubaker, Bryan Ang, Syril Dorairaj

    This study aimed to evaluate the safety profile and clinical efficacy of the VIA360™ Surgical System (VIA360) for ab-interno canaloplasty in the management of glaucoma. This retrospective, noncomparative chart review included 64 eyes undergoing standalone VIA360 ABiC (VIA360-Alone) or VIA360 combined with cataract surgery (VIA360–Cataract) between March 13, 2025, and January 7, 2026. Surgical success was defined as ≥20% intraocular pressure (IOP) reduction at the last follow-up without surgical reintervention. Changes in IOP, glaucoma medications, and best-corrected visual acuity (BCVA) were evaluated through 6 months. At 6 months, mean IOP decreased from 18.46 to 14.07 mmHg (−4.39 mmHg; −23.78%; P < 0.0001). In subgroup analysis, VIA360–Cataract eyes showed a reduction from 17.61 to 13.48 mmHg (−4.13 mmHg; −23.45%; P = 0.0011), while VIA360-Alone eyes decreased from 20.61 to 16.15 mmHg (−4.46 mmHg; −21.69%; P = 0.0549). Glaucoma medication use also decreased from 1.46 to 1.13 medications (−22.6%; P = 0.1331) overall at 6 months, with greater reductions observed in the combined group compared with standalone cases. Surgical success was achieved in 15 of 29 eyes (51.72%) with available follow-up. No intraoperative complications or vision-threatening adverse events were observed. These findings suggest that VIA360 provides clinically meaningful IOP reduction with an excellent safety profile in early postoperative outcomes, demonstrating greater consistency when performed in conjunction with cataract surgery. Larger prospective studies are warranted to further define long-term durability.